Borean Pharma AS

Borean aims to leverage the trimeric properties of one human protein, tetranectin, to develop second-generation protein therapeutics to treat autoimmune disease and cancer. Its first candidate is a TNF-alpha antagonist in preclinical testing for autoimmune diseases, but the company also has ongoing early work on several undisclosed oncology targets.